×
About 14,903 results

ALLMedicine™ Atopic Dermatitis Center

Research & Reviews  4,679 results

Fanning the Flames: IRAK2 Signaling in Differentiated Epithelium Potentiates Skin Infla...
https://doi.org/10.1016/j.jid.2021.04.006
The Journal of Investigative Dermatology; Castillo R, Subudhi I et. al.

Sep 26th, 2021 - Aberrant epidermal differentiation is a hallmark of inflammatory skin diseases, including psoriasis and atopic dermatitis. If and how differentiated epidermal cells contribute to inflammatory pathology is unclear. In their new article in the Journ...

The Use of Biologics During the COVID-19 Pandemic.
https://doi.org/10.1016/j.det.2021.05.010
Dermatologic Clinics; Jones ME, Kohn AH et. al.

Sep 25th, 2021 - During the coronavirus disease 2019 (COVID-19) pandemic, there has been considerable discussion regarding the use of biologics in patients with inflammatory skin conditions, such as psoriasis, hidradenitis suppurativa, and atopic dermatitis. This ...

Increasing Severity of Early-Onset Atopic Dermatitis, But Not Late-Onset, Associates wi...
https://doi.org/10.1111/all.15108
Allergy Schoos AM, Chawes BL et. al.

Sep 25th, 2021 - Early exposure to allergens through a defect skin barrier has been proposed as a mechanism for inducing sensitization and development of allergic diseases. We hypothesized that early-onset, severe atopic dermatitis (AD) is associated with developm...

Progressive B cell depletion in human MALT1 deficiency.
https://doi.org/10.1111/cei.13662
Clinical and Experimental Immunology; Sonoda M, Ishimura M et. al.

Sep 25th, 2021 - MALT1-deficiency is a rare combined immunodeficiency characterized by recurrent infections, dermatitis and enteropathy. We herein investigate the immunological profiles of our patient and previously reported children with MALT1-deficiency. A mutat...

IL-33 Signaling in Sensory Neurons Promotes Dry Skin Itch.
https://doi.org/10.1016/j.jaci.2021.09.014
The Journal of Allergy and Clinical Immunology; Trier AM, Mack MR et. al.

Sep 25th, 2021 - Chronic pruritus, or itch, is common and debilitating, but the neuro-immune mechanisms that drive chronic itch are only starting to be elucidated. Recent studies demonstrate that the IL-33 receptor (IL-33R) is expressed by sensory neurons. However...

see more →

Guidelines  8 results

Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis...
https://www.ncbi.nlm.nih.gov/pubmed/33147660
Dermatology Online Journal; Yim RM, Singh I et. al.

Nov 5th, 2020 - Owing to the evolving COVID-19 pandemic and emerging data regarding immunosuppressant therapies for inflammatory cutaneous diseases, dermatologists are being encouraged to reevaluate their patients' treatment regimens to minimize any potential ris...

Considerations on biologicals for patients with allergic disease in times of the COVID-...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300800
Allergy Vultaggio A, Agache I et. al.

Jun 6th, 2020 - The outbreak of the SARS-CoV-2-induced coronavirus disease 2019 (COVID-19) pandemic re-shaped doctor-patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex pat...

European task force on atopic dermatitis position paper: treatment of parental atopic d...
https://doi.org/10.1111/jdv.15709
Journal of the European Academy of Dermatology and Venere... Vestergaard C, Wollenberg A et. al.

Jun 25th, 2019 - Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific recommendations for the trea...

Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) ...
https://doi.org/10.1111/jdv.14891
Journal of the European Academy of Dermatology and Venere... Wollenberg A, Barbarot S et. al.

Apr 21st, 2018 - This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines as well as patients. It is a consensus-based guideline, taking available evidence from other guidelines, systematic revi...

The microbiome in allergic disease: Current understanding and future opportunities-2017...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899886
The Journal of Allergy and Clinical Immunology; Huang YJ, Marsland BJ et. al.

Mar 5th, 2017 - PRACTALL is a joint initiative of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology to provide shared evidence-based recommendations on cutting-edge topics in the field of allergy and ...

see more →

Drugs  431 results see all →

News  841 results

Proposed Classification Framework for Atopic Dermatitis Unveiled
https://www.medscape.com/viewarticle/954902

Jul 16th, 2021 - The heterogeneous clinical course of atopic dermatitis (AD) and its differing signs, symptoms, burden, and response to treatment can pose a quandary for physicians. Dr Jonathan Silverberg This is behind a new classification framework called DESCRI...

Dupilumab Safe, Effective in Kids 6-11 With Moderate-to-Severe Asthma
https://www.medscape.com/viewarticle/954586

Jul 10th, 2021 - Dupilumab (Dupixent, Sanofi and Regeneron) significantly reduced exacerbations compared with placebo in children ages 6-11 years who had moderate-to-severe asthma in a phase 3 trial. A fully human monoclonal antibody, dupilumab also improved lung ...

Study Provides Insights Into Pediatric Psoriasis Over Two Decades
https://www.medscape.com/viewarticle/954411

Jul 8th, 2021 - Obesity, atopic dermatitis, psychiatric disease, and arthritis are the most common comorbidities among infants, children, and adolescents with psoriasis, while predictors of moderate to severe disease include morphology, non-White race, and cultur...

Expert Shares Practical Considerations for Dupilumab Treatment
https://www.medscape.com/viewarticle/954120

Jul 1st, 2021 - Clinicians who struggle to get dupilumab approved for their patients with moderate to severe atopic dermatitis (AD) are not alone. This scenario was illustrated in a 2020 retrospective study of 179 adults with AD who were cared for at the Universi...

Baricitinib Found Effective for Moderate to Severe AD Out to 52 Weeks
https://www.medscape.com/viewarticle/953944

Jun 29th, 2021 - Baricitinib, at a dose of 2 mg a day, demonstrated efficacy in adults with moderate to severe atopic dermatitis up to 52 weeks, integrated data from two trials demonstrated. "With long-term therapy, the baricitinib 2 mg response remains stable or ...

see more →

Patient Education  2 results see all →